A B S T R A C T Insulin-induced hypoglycemia by unknown mechanism(s) increases plasma arginine vasopressin (AVP) levels in humans. Mechanisms for increased AVP levels during central nervous system glucoprivation were investigated by administering 20-min i.v. infusions of 2-deoxy-D-glucose (50 mg/kg), a competitive inhibitor of glucose utilization, or normal saline (sham), to 24 normal volunteers. Some of the infusions were administered in combination with neuropharmacological blocking agents (placebo). The behavioral, physiological, metabolic, and hormonal correlates of 2-deoxy-D-glucose (2DG)-induced glucoprivation and AVP secretion were studied in a group (n = 5) pretreated for 1 wk with either mazindol (1 mg per os three times per day), a potent norepinephrine and dopamine-reuptake blocker, or placebo. A second group (n = 5) received either propranolol (3 mg/3 min followed by 80 ,tg/min) or normal saline infusion before and during 2DG administration. With 2DG alone, plasma AVP levels increased from 1.3 + 0.3 pg/ml at base line to a peak of 4.5+1.4 pg/ml at 60 min and remained elevated for 150 min. From 30 to 180 min after 2DG administration, the 2DG-infused volunteers increased their water intake in comparison with shaminfused volunteers. Marked increases in epinephrine and slight increases in norepinephrine were associated with increases in plasma glucose and renin activity and decreases in plasma potassium. Plasma sodium and osmolality increased transiently and mean arterial pressure (MAP) fell. These changes, however, were small and inconstant and could not account for the observed increases in thirst and AVP levels. Pretreatment with mazindol prevented the decrease in MAP and the increase in plasma renin activity (PRA) following 2DG infusions without modifying increased thirst, water intake, or AVP responses to glucoprivation. Pretreatment with propranolol effectively blocked ,3-adrenoreceptors as evidenced by increased MAP and plasma epinephrine, and abolition ofthe RPA increases during 2DG-induced glycoprivation, but did not suppress AVP and thirst responses. A cervical cordsectioned patient lacking descending sympathetic outflow had a potentiated thirst response to 2DG-induced glucoprivation in the absence of increases in sodium, catecholamines, and PRA. Thus 2DG administration activates mechanisms for increased thirst and AVP which are unrelated to changes in peripheral catecholamines, MAP, PRA, and osmolality.
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A B S T R A C T Insulin-induced hypoglycemia by unknown mechanism(s) increases plasma arginine vasopressin (AVP) levels in humans. Mechanisms for increased AVP levels during central nervous system glucoprivation were investigated by administering 20-min i.v. infusions of 2-deoxy-D-glucose (50 mg/kg), a competitive inhibitor of glucose utilization, or normal saline (sham), to 24 normal volunteers. Some of the infusions were administered in combination with neuropharmacological blocking agents (placebo). The behavioral, physiological, metabolic, and hormonal correlates of 2-deoxy-D-glucose (2DG)-induced glucoprivation and AVP secretion were studied in a group (n = 5) pretreated for 1 wk with either mazindol (1 mg per os three times per day), a potent norepinephrine and dopamine-reuptake blocker, or placebo. A second group (n = 5) received either propranolol (3 mg/3 min followed by 80 ,tg/min) or normal saline infusion before and during 2DG administration. With 2DG alone, plasma AVP levels increased from 1.3 + 0.3 pg/ml at base line to a peak of 4.5+1. 4 Receivedfor publication 27 May 1979 and in revisedform 3 September 1980. and slight increases in norepinephrine were associated with increases in plasma glucose and renin activity and decreases in plasma potassium. Plasma sodium and osmolality increased transiently and mean arterial pressure (MAP) fell. These changes, however, were small and inconstant and could not account for the observed increases in thirst and AVP levels. Pretreatment with mazindol prevented the decrease in MAP and the increase in plasma renin activity (PRA) following 2DG infusions without modifying increased thirst, water intake, or AVP responses to glucoprivation. Pretreatment with propranolol effectively blocked ,3-adrenoreceptors as evidenced by increased MAP and plasma epinephrine, and abolition ofthe RPA increases during 2DG-induced glycoprivation, but did not suppress AVP and thirst responses. A cervical cordsectioned patient lacking descending sympathetic outflow had a potentiated thirst response to 2DG-induced glucoprivation in the absence of increases in sodium, catecholamines, and PRA. Thus 2DG administration activates mechanisms for increased thirst and AVP which are unrelated to changes in peripheral catecholamines, MAP, PRA, and osmolality. INTRODUCTION Central nervous system (CNS)1 glucoprivation induced by infusions of 2-deoxy-D-glucose (2DG), a competitive inhibitor of glucose transport (1) and phosphohexoisomerase activity (2) , increases anterior pitui-tary hormone secretion (3, 4) , catecholamine-dependent renin release (5) , and plasma free fatty acid and glucose levels through activation of descending sympathetic adrenomedullary pathways (6) . Infusion of 2DG in humans induces eating and drinking, as well as a relative insulinopenia characteristic ofthe diabetic state (7) .
Insulin-induced hypoglycemia increases water intake in rats (8) and plasma arginine vasopressin (AVP) in rats (9) and humans (10) . Since insulin-induced hypoglycemia increases renin secretion (11) , Fitzsimons (12) has suggested that the renin-angiotensin system may activate drinking during hypoglycemia. Stimuli that increase AVP secretion, such as increased osmolality (13) and angiotension II (14) levels and decreased blood volume and pressure (15) may also activate drinking.
We investigated the effects of glucoprivation on water intake and AVP levels by infusing healthy male volunteers with 2DG. Metabolic, hormonal, and physiological correlates of 2DG-induced glucoprivation were measured in healthy volunteers and in a cervical cord-sectioned patient to determine which, if any, might be related to any observed changes in thirst and AVP secretion. To eliminate two potential peripheral water balance control mechanisms (hypotension and hyperreninemia), mazindol (Sanorex, Sandoz Pharmaceuticals Inc., Hanover, N. J.), a blocker of norepinephrine (NE) and dopamine reuptake (16) (sham) infusions, these subjects also took placebo capsules for 1 wk before 2DG (sham) infusions. Of the seven subjects who received a 2DG infusion after 1 wk of placebo treatment, five also received another 2DG infusion after 1 wk of mazindol (1 mg TID po) pretreatment in a randomized, paired design. Five other subjects were pretreated with mazindol for 1 wk before receiving a sham infusion to determine the effects of mazindol alone on behavioral and hormonal responses.
In a second set of experiments, five subjects received two 2DG infusions randomly paired with propranolol (3 mg/3-min loading dose followed by 80 ,ug/min continuous infusion) or a normal saline (sham) infusion. The effects of intravenous propranolol alone were evaluated in the 30-min base-line period before 2DG infusion. Finally, one patient with transsection of the spinal cord between the 5th and 6th cervical vertebrae gave informed consent to receive a 2DG infusion.
Individuials were deprived of food overnight, but could drink tap water at room temperature (21°C) ad lib. before and durinig the experiment. The experimenter unobtrusively measured water ingested from a 250-ml opaque cup, at 30-min intervals, before and after the 2DG infusion. (13) . Insulin (Amersham/Searle Corp., Arlington Heights, Ill.) and aldosterone (Diagnostic Products Corp., Los Angeles, Calif.) plasma levels were determined by radioimmunoassay. Blood samples for plasma renin activity (PRA) were collected at 60-min intervals after 2DG infusion in chilled tubes containing 5 mM EDTA. PRA was determined by the Beckton Dickinson, Orangeburg, N. Y.) radioimmunoassay kit for angiotensin I generated in a 3-h incubation at pH 7.4. Blood for catecholamine determinations was collected in chilled heparinized tubes containing enough reagents to produce a solution buffered to pH 5.5 of 4 mM reduced glutathione and 5 mM EGTA after addition of whole blood. NE and epinephrine (E) were measured by a modified single isotope derivative radioenzymatic assay (19, 20) in which standard curves are developed for each subject's samples using plasma from the same subject on the day of the experiment. The intraassay coefficients of variation are 6.7 and 5.2% for E and NE at concentrations of 90 and 320 pg/ml, respectively. The interassay coefficients of variation are 9.3 and 9.4% for E and NE at concentrations of 39 and 250 pg/ml, respectively.
Plasma was separated and stored at -20°C. Glucose and osmolality determinations were performed immediately. Catecholamine 
RESULTS
Side effects from 2DG infusions included a 0.90C fall in tympanic membrane temperature, marked diaphoresis with increased feelings of warmth and tiredness, 10 to 15 beats/min pulse rate increase, augmented ratings of hunger, and increased food intake 3 h after 2DG infusion. AVP levels increased significantly at 60, 90, and 150 min after 2DG infusion with a peak 3.8-fold (4.5±1.4 pglml after 2DG vs. 1.2±0.4 pg/ml after sham infusion) elevation occurring at 60 min, but did not change in sham-infused subjects (Fig. 1) . Subjects drank more water (P < 0.01) during 2DG-induced glucoprivation (481±121 ml) than during sham infusion (84±16 ml) with the peak response occurring at 120 min ( Fig. 1) . Thirst ratings increased from -1.4 ±2.2 mm at 0 min to 21.4±11.1 mm at 60 min and remained elevated until 120 min in the placebo-2DG-treated subjects, but did not change in placebo-sham-infused subjects.
Plasma osmolality did not increase significantly in association with 2DG-induced drinking and AVP increases. At 60 min, plasma osmolality increased insignificantly from 283.3 to 284.8 mosmol/kg while AVP increased 3.2 pg/ml. Simultaneously, sodium levels transiently increased from 138.2 to 139.0 meq/liter (P < 0.05) and glucose levels rose from 82 to 138 mg/dl (P < 0.01), while potassium levels decreased from 3.8 to 3.3 meq/liter (P < 0.01). Sodium levels were not significantly elevated after 60 min, but AVP levels and water intake remained elevated until 150 and 180 min, respectively. Potassium levels declined from 3.8 to 3.2 meq/liter at 90 min and remained reduced while glucose levels progressively increased until a peak response 108% greater than base-line was attained at 150 min. Insulin levels increased from 10.4 ,uU/ml to 164, 192, and 310% of base line in association with 68, 93, and 105% increases in glucose at 60, 120, and 180 min, respectively. MAP calculated from blood pressures obtained by auscultation decreased from a base-line of 78-72 mm Hg at 60 min and remained reduced until 180 min. Plasma E levels increased from 17 to 949 pg/ml while plasma NE levels increased only slightly from 175 to 284 pg/ml at 60 min. E levels remained elevated throughout the post-2DG stimulation period, whereas NE levels were no longer significantly elevated at 180 min. PRA levels increased from 0.53 to 1.41 ng/ml per h 60 min after 2DG administration and remained increased until 180 min. At 60 and 90 min aldosterone levels increased, respectively, 79 and 69% above baseline levels of 64 PRA, decreases in potassium, and no change in sodium.
In sham-infused subjects (n = 7), plasma osmolality, sodium, glucose, potassium, catecholamines, PRA, and MAP did not change. Mazindol administration in five volunteers did not affect baseline thirst and AVP values or overall thirst, water intake, and AVP response to 2DG-induced glucoprivation (Fig. 2) , but did prevent 2DG-induced hypothermia. Total water intake of 562+97 ml after 2DG infusion during mazindol pretreatment was not different from 583+138 ml during placebo pretreatment. Compared to basal levels, plasma AVP levels increased 60 and 90 min after 2DG in both placebo-and mazindoltreated subjects.
Pretreatment with mazindol suppressed plasma osmolality responses to 2DG at 30, 60, and 150 min Thirst, Vasopressin, and 2-Deoxy-D-glucose Glucoprivation ( Table I ). Mazindol pretreatment did not suppress water intake and AVP increases following 2DG (Fig.  2 ) even though plasma osmolalities remained virtually unchanged from base-line (Table I) . Sodium levels were lower at 120 and 150 min after 2DG infusion in mazindol-pretreated subjects compared to placebopretrea'ted subjects (Table I) . Water intakes and AVP levels, however, showed no corresponding differences at those time points (Fig. 2 ). Potassium levels (Table I) did not differ between placebo-and mazindol-treated group. Mazindol also failed to alter the glucose and insulin responses to 2DG (Table I) . Mazindol pretreatment prevented any slight fall in MAP following 2DG infusions (Fig. 2) . MAP were higher 60 to 180 min after 2DG infusion during mazindol therapy compared to placebo treatment (Fig. 2) . Mazindol pretreatment did not alter the plasma E response to 2DG (Fig. 2) . NE levels increased slightly but not significantly during both placebo and mazindol treatment periods. However, during mazindol treatment, NE levels ( Fig. 2) at 180 min (364±69 pg/ml) were greater (P < 0.05) than those during placebo therapy (258±51 pg/ml). During placebo treatment PRA increased (P < 0.05) 195%, 155%, and 114% above baseline at 60, 120, and 180 min, respectively, after 2DG infusion. During mazindol therapy 2DG infusion transiently increased PRA only 16% (P < 0.05) at 60 min. Furthermore, mazindol therapy suppressed both PRA (Fig. 2) and aldosterone (Table I) Mazindol administration to five sham-infused subjects did not change water intake or plasma AVP levels for 180 min after the infusions (Fig. 1) . Furthermore, plasma osmolality, sodium, potassium, glucose, catecholamine, and PRA levels and MAP in sham-infused subjects (data not shown) were unaltered by mazindol pretreatment.
Propranolol infusions did not alter the thirst, water intake, and AVP response to 2DG-induced glucoprivation (Fig. 3) . Consistent with its lack of effect on the hyperglycenlic response to 2DG, propranolol also failed to prevent smiiall increases in osmolality (Table  II) . No significant increases in sodium levels were ol)served after 2DG infttsioni, and there were no differences in sodiumnl levels between propranolol-aind shacm-infused grouips (Table II) . In associationv with 2DG-induiced hyperglycemlia, potassium levels decreased from 4.3 ±0.3 to 3.6+0.2 meq/liter at 90 mmin and remained depressed iunitil 180 min (Table II) . Propraniolol infusion not only prevented the developmenit of hvpokalemia, btit, in fact, raised potassiumii levels (Table II) between 60 and 180 min after 2DG infusion in association with increased catecholamine and blood pressure levels (Fig. 3) . The peak potassium value of 4.6-+0.1 meq/liter at 150 min was greater than both the base-line potassium of 4.0+0.1 me(l/liter(P < 0.01) and the potassium value of 3.4+0.1 meq/liter (P < 0.01) observed 150 min after 2DG infuision alone. Propraniolol infuision did not reduce the hyperglycemic response to 2DG until 180 mnii (Table II) . In contrast, propraniol pretreatment comiipletely abolished the hyperinsulinemic response to 2DG-induced hyperglycemia (Table II) . Although propranolol infusions did not alter the increased AVP, thirst, aind water intake responses observed after 2DG infusions (Fig. 3) , unopposed aadrenoreceptor sti mitilation dunring 8-adrenoreceptor blockade increased MAP from 82±5 mm Hg at base line to 100+5 mm Hg at 180 min. MIAP did not change in 2DG-sham-infusecl stibjects having blood pressuires monitored automatically (Fig. 3) . Plamsa E levels increased more than twice as much after propranolol and 2DG infusionis thaln after 2DG alone (Fig. 3) . Plasma NE increased after 2DG in 1)oth sham-and propranololtreated subjects (Fig. 3) . In the absence of propranolol, PRA increased from 0.77±0.11 ng/ml per h at 0 min to a peak of' 3.66±+1.19 ng/mll per h (P < 0.05) at 120 mIi followinig 2DG (Fig. 3) . 8-adrenoreceptor blockade completely suppressed the PRA respoInse to 2DG without diminishinig thirst anid AVP responses (Fig. 3) . In associationi wvith increases in potassiumll and MAP, aldosteronie levels increased markedly while PRA levels did not change duiring 8-adrenoreceptor blockade after 2DG infutsions (Table II) . Propracnolol adminiistration lbefore 2DG infuisionis did not change basal AVP, E, and NE levels, MIAP, thirst anid water intake (Fig. 3) , osm-nolalitv, sodium, potassiumn, and glucose levels (Table II) , 1)ut did slightly reduce PRA (Fig. 3) .
Thirst ratings in a cervical cord-sectioned patient increased fromii 60 to 150 min after 2DG infuision (Fig.  4) . During the same time period water intakes were three to eight times greater in the cervical cordsectioned patient receiving 2DG. The cervical cordsectioned patient drank a total of 2,450 ml while normal volinteers drank onl 548+118 ml after 2DG infusion. This miiarked increase in xvater intake in the cervical cord-sectioned patieint occurred in the absence of significanit inereases in catecholamines, PRA, glucose, and sodiumll concenitration (Fig. 4) (a) hypothalamic-pituitary responses including increased levels of prolactin, growth hormone, and corticol (3, 4); (b) hypothermia (7, 21) ; and c increased food and water intake (7). Cervical cord-sectioned patients have a similar but potentiated hormonal and behavioral response to 2DG (3, 4, 22) . These potentiated responses may be related to a lack of descending sympathetic outflow and deficient glucocounter-regulation associated with markedly reduced catecholamine secretion (3) . The present study shows that 2DG-induced CNS glucoprivation activates mechanisms for water conservation. Potential factors including hyperosmolality (23) , hypotension (15) , /B-adrenoreceptor stimulation (24) , and hyperreninemia (14) for stimulating thirst and AVP release during glucoprivation were systematically studied in a cervical cord-sectioned patient and by administering neuropharmacological blocking agents to normal volunteers to eliminate various peripheral mechanisms.
Several considerations suggest that the dipsogenic and vasopressinemic effects of 2DG were not due to osmotic stimulation. Although osmolality increased slightly (1.5 mosmol/kg) at 60 min following 2DG infusion, this increase was neither significant nor sufficiently large to account for a 3.2 pg/ml increase in AVP (15) . Moreover, it could be explained entirely by a 56 mg/dl increase in glucose, which by itself is not an effective osmotic stimulus for increasing AVP under conditions of euhydration (23) . Small increases (0. meq/liter) in sodium levels were observed after 2DG in one experiment but were not evident in all cases (Table  II) and, in any event, were not large enough to account for a 3.2 pg/ml increase in AVP. Finally, a cervical cordsectioned patient markedly increased water intake after 2DG in the absence ofany sodium or glucose elevations (Fig. 4) . Thus thirst, water intake, and AVP levels increased in the absence of elevated effective osmolality and cation levels which might otherwise stimulate behavioral and physiological mechanisms for increasing hydration. With marked increases in water intake and AVP levels after 2DG infusion, decreases in plasma osmolality and sodium levels might be expected but were not observed except in the cervical cord-sectioned patient, who had no increase in glucose levels and who drank 2,450 ml of water. Thus the absence of decreases in osmolality may be due to contributions to measured plasma osmolality levels from increased glucose levels and to shifts of sodium from intracellular to extracellular space associated with movement of potassium into cells. Alternatively, increased renal conservation of sodium through activation of the renin-aldosterone system (Table II) and decreased filtered load or altered renal tubular reabsorption ofsodium in association with a peak 33% reduction in renal plasma flow as measured by p-aminohippurate clearance (25) could explain the absence of significant decrements in sodium levels after water ingestion. Since both PRA (Fig. 2) and aldosterone increases (Table I) after 2DG were suppressed by mazindol administration, it is not surprising that osmolality and sodium levels were correspondingly somewhat lower after 2DG in subjects pretreated with mazindol (Table I) . In contrast, although propranolol administration blocked PRA responses to 2DG (Fig. 3) , plasma aldosterone levels increased markedly during ,8-adrenoreceptor blockade (Table II) . Thus, no reduction in osmolality or sodium levels during ,8-adrenoreceptor blockade would be expected, nor was it seen (Table II) .
In contrast to the hypokalemia produced by 2DG administration alone (Table II) , hyperkalemia was observed after 2DG in propranolol-treated subjects. This may be due to blockade of a /3-adrenoreceptor mechanism for extrarenal disposal of potassium (26) . Increases in potassium levels in spite ofhyperglycemia are unexplained but may be related to unopposed aadrenoreceptor-mediated effects on potassium homeostasis since, during E infusions, f8-adrenoreceptor blockade with propranolol permits development of hyperkalemia which can be blocked by administering a-adrenoreceptor antagonists such as phentolamine (27) .
Potentiation of the aldosterone response to 2DG administration during /3-adrenoreceptor blockade (Table   II) could be a result of hyperkalemia (28) or decreased metabolic clearance of aldosterone (29) , but would be expected to decrease, not increase, plasma potassium levels. The absence of an insulin response to 2DG during propranolol infusions might preclude the development of hypokalemia (30) , but does not by itself explain the development of hyperkalemia. Further- MINUTES FIGURE 4 Effect of 50 mg/kg 2DG infuised from 0 to 20 mi on mean+SEM thirst ratings, water intake, plasma sodiuim, E, NE, PRA, and plasma glucose in a cervical cord-sectioned patient (e) and five normal subjects (shaded area).
more, other studies have indicated that small changes in insulin levels may not be sufficient to account for increased intracellular potassium uptake during hyperepinephrinemia or decreased intracellular potassium uptake found during /3-adrenoreceptor blockade (26) . Thus, the findings of the present studies are consistent with an a-adrenoreceptor-mediated mechanism for producing hyperkalemia (27) , or blockade of a ,8-adrenoreceptor-mediated mechanism for diminishing potassium levels (26) . Peak AVP response occurred at 60 min while peak water intake occurred at 120 min after 2DG infusion, indicating that AVP secretion did not correlate well with water intake. Such a dissociation between AVP release and initiation of water drinking has been shown previously in dogs receiving hypertonic saline infusion (31) . This temporal dissociation in response is unexplained but may indicate different mechanisms of control or different rates of response to a common control mechanism.
Nonosmotic factors including decreases in MAP (12, 15) , changes in peripheral catecholamines (12, 24) , and hyperreninemia (12, 14) did not provide the dipsogenic and vasopressinemic stimuli during 2DG-induced glucoprivation. The small (0-7.2%) decreases in MAP recorded in one of the present studies did not occur in others (Fig. 3) and, in any event, was insufficient to increase AVP levels 3-4 pg/ml (15) . Moreover, mazindol administration eliminated any fall in MAP without diminishing the thirst and AVP responses to 2DG (Fig. 2) . Finally, propranolol administration not only prevented any decrease after 2DG, but actually increased MAP 20.7%, without reducing thirst and AVP responses (Fig. 3) . Therefore, it is unlikely that hypotension plays any role in the AVP and thirst response to 2DG-induced glucoprivation.
Increases Activation of descending sympathetic pathways after 2DG-induced glucoprivation increases plasma levels of E, and to a lesser degree, NE. The increase in plasma E is associated with increases in thirst and AVP levels. Infusion of the /3-adrenoreceptor agonist, isoproterenol, increases antidiuretic hormone response, while infusion of the a-adrenoreceptor agonist, NE, reduces antidiuretic hormone activity (24) . Although it is possible that catecholamines affect AVP release and thirst through activation of a peripheral baroreceptor mechanism (24) , or by stimulation ofa CNS mechanoreceptor (33) (Fig. 3) . The effectiveness of,-adrenoreceptor blockade with propranolol was established by finding a doubling of the hyperepinephrinemia normally seen after 2DG administration, an increase in MAP, and elimination of the renin response (Fig. 3) . Potentiation of 2DG-induced hyperepinephrinemia by /3-adrenoreceptor blockade may be related to a reduction in metabolic clearance of E, unopposed stimulation of a-adrenoreceptor-mediated neurotransmitter mechanisms, or blockade of critical /3-adrenoreceptor negative feedback neurotransmitter systems in the CNS at the adrenal medulla. Raised E levels with /-adrenoreceptor blockade during insulin-induced glucopenia have been reported by others (32) . Also, since propranolol passes the blood-brain barrier, /8-adrenoreceptors located in the CNS are unlikely to be involved in the dipsogenic and vasopressinemic response to 2DG. Third, marked increases in thirst and water intake were produced by 2DG administration to a cervical cord-sectioned patient, who had no evidence of increased plasma E levels after 2DG (Fig. 4) .
Finally, peripheral NE increases (Fig. 3) (Figs. 2 and 3) . Since angiotensin II infusions are known to increase AVP in man (14) and thirst in rats (12) , it is possible that 2DG-induced glucoprivation induces thirst and AVP secretion by activation of the peripheral renin-angiotensin system. This possibility is excluded by the following: First, both mazindol (Fig. 2) and propranolol (Fig. 3) administration suppressed PRA response to 2DG without diminishing the thirst and AVP responses. Second, 2DG failed to increase PRA levels in a cord-sectioned patient who nonetheless drank enormous quantities of water (Fig. 4) . Finally, these observations are consistent with those of others who have reported no correlation betwen PRA and AVP levels in man during various states of hydration and volume depletion (36) , and no diminution of the AVP response to orthostasis during propranolol blockade which, nevertheless, eliminated the PRA response to orthostasis (37) . Since angiotensin II may act as a neurotransmitter in some hypothalamic areas it is still possible that central angiotensin II mediates the dipsogenic and vasopressinemic response to 2DG.
Although there is little evidence to suggest that hypersulinemia plays a direct role in the release of AVP and the stimulation of thirst, it is possible. Earlier studies have indicated that insulin levels do not change (3), or increase only slighly (21) , relative to the hyperglycemia observed after 2DG infusions. In the present study the gradual rise in insulin levels was less than what might be expected for the level of hyperglycemia (38) . This relative insulinopenia may be related to activation of catecholaminergic mechanisms controlling insulin secretion (39) and can be converted into an absolute insulinopenia by administering the ,p-blocking agent, propranolol (Table II) . AVP levels and thirst, nonetheless, increased in the absence of an insulin response to 2DG during /8-adrenoreceptor blockade. Thus, changes in plasma insulin do not mediate the effects of 2DG on thirst and AVP.
While hypovolemia may stimulate thirst (12) and vasopressin secretion (15) , it is unlikely that this played a role in the thirst and AVP response to 2DG since normal saline was infused to replace the volume of blood withdrawn and because blood volume decreases <5% as indicated by increases in hematocrit of <2% after 2DG infusions (40) , whereas >10% fall in blood volume is necessary to stimulate AVP secretion in man (15) .
Finally, increases in AVP levels may be the result of decreased metabolic clearance. A 20-30% decrease in renal plasma flow (25) could account for some AVP increases, but this effect on AVP levels would most likely be more prolonged than the one we observed. Furthermore, mazindol and propranolol administration eliminated both the MAP fall and secondary PRA increases after 2DG infusions, without affecting AVP and thirst responses. Thus, changes in renal clearance are unlikely to account for the increased AVP response to 2DG infusions. This conclusion is strengthened by the fact that thirst, a centrally determined event presumably occurring in parallel with activation of AVP release mechanisms, increased under all 2DG treatment conditions studied.
The findings from this investigation, in which AVP and thirst responses have been dissociated from peripheral mechanisms of control, and in related studies in which glucoprivation has been induced in cervical cord-sectioned patients (22) , suggest that thirst and hunger, water and food intake, and AVP secretion, are under the control of CNS pathways whose functions are sensitive to changes in glucose metabolism.
